| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
110.97(B) |
| Last
Volume: |
1,917,610 |
Avg
Vol: |
1,564,458 |
| 52
Week Range: |
$366.54 - $513.76 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 16.7 |
| Insider 3/6 Months : 17.3 |
|
| Guru Rank Number : 180 |
| Guru Rank Value : 7.8 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
15,000 |
15,000 |
15,000 |
| Total Buy Value |
$0 |
$5,844,184 |
$5,844,184 |
$5,844,184 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
76,752 |
76,752 |
116,349 |
357,265 |
| Total Sell Value |
$33,762,152 |
$33,762,152 |
$52,909,432 |
$160,733,410 |
| Total People Sold |
4 |
4 |
8 |
13 |
| Total Sell Transactions |
5 |
5 |
28 |
91 |
| End Date |
2025-08-24 |
2025-05-23 |
2024-11-22 |
2023-11-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carney Lloyd |
Director |
– • – |
2025-11-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
800 |
6,315 |
|
- |
|
| Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
• – – |
2025-11-17 |
4 |
AS |
$434.58 |
$1,086,450 |
D/D |
(2,500) |
16,852 |
|
-2% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2025-11-14 |
4 |
AS |
$440.30 |
$23,624,306 |
D/D |
(53,604) |
24,026 |
|
-2% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2025-11-14 |
4 |
OE |
$86.52 |
$4,700,491 |
D/D |
53,604 |
77,630 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2025-11-13 |
4 |
AS |
$440.22 |
$8,668,014 |
D/D |
(19,688) |
24,026 |
|
-2% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2025-11-13 |
4 |
OE |
$91.05 |
$1,792,592 |
D/D |
19,688 |
43,714 |
|
- |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2025-10-02 |
4 |
AS |
$404.21 |
$280,522 |
D/D |
(694) |
15,653 |
|
4% |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2025-10-01 |
4 |
D |
$400.00 |
$503,600 |
D/D |
(1,259) |
16,347 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2025-08-27 |
4 |
AS |
$386.69 |
$102,860 |
D/D |
(266) |
4,565 |
|
10% |
|
| Sachs Bruce I |
Director |
– • – |
2025-08-06 |
4 |
B |
$389.36 |
$1,948,416 |
D/D |
5,000 |
45,000 |
2.39 |
10% |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2025-08-06 |
4 |
B |
$389.08 |
$3,895,768 |
D/D |
10,000 |
115,968 |
2.81 |
10% |
|
| Mckechnie Duncan |
EVP, Chief Commercial OfficerO |
• – – |
2025-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,130 |
|
-8% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2025-07-01 |
4 |
D |
$450.23 |
$16,767,916 |
D/D |
(37,243) |
63,368 |
|
- |
|
| Altshuler David |
EVP, Chief Scientific Officer |
• – – |
2025-05-15 |
4 |
AS |
$424.69 |
$22,084 |
D/D |
(52) |
23,281 |
|
-13% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2025-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
37,622 |
100,611 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2025-05-02 |
4 |
AS |
$505.86 |
$202,344 |
D/D |
(400) |
4,831 |
|
-21% |
|
| Thornberry Nancy |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
398 |
2,035 |
|
- |
|
| Upadhyay Suketu |
Director |
– • – |
2025-05-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,001) |
2,354 |
|
- |
|
| Upadhyay Suketu |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
796 |
3,355 |
|
- |
|
| Mckenzie Diana |
Director |
– • – |
2025-05-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,001) |
2,231 |
|
- |
|
| Mckenzie Diana |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
796 |
3,232 |
|
- |
|
| Schneider Jennifer |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
796 |
1,718 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
796 |
5,231 |
|
- |
|
| Carney Lloyd |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
796 |
7,115 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
398 |
6,872 |
|
- |
|
1553 Records found
|
|
Page 1 of 63 |
|
|
4.44 (1.05%) 
